Fig. 4: Effect of AAV7m8 gene transfer on visual acuity and RGC in ONC.

OKR recordings demonstrate significantly decreased visual acuity in eyes of ONC mice treated with AAV2-eGFP (nā=ā10; experiments performed in triplicate) compared with Sham injured mice (nā=ā10; experiments performed in tripicate ***pā=ā0.002). A Treatment with AAV7m8-SIRT1 (nā=ā15; experiments performed in tripicate) showed a significant delay in loss of visual function in ONC (nā=ā10; experiments performed in tripicate) compared with Sham injured mice (nā=ā10; experiments performed in tripicate) (*pā=ā0.03) on visual acuity seen in peach area outlined in the graph. B RGC flat mount counts demonstrate significantly decreased numbers in eyes of ONC mice treated with AAV2-eGFP (nā=ā10; experiments performed in tripicate) compared with Sham injured mice (nā=ā10; experiments performed in triplicate; ***pā=ā0.001). Treatment with AAV7m8-SIRT1 (nā=ā10; experiments performed in tripicate) showed a significant increase in retinal ganglion cell counted per flat month function in ONC (nā=ā7) compared with control ONC mice (nā=ā10; experiments performed in tripicate) (*pā=ā0.03). C Representative RGC counts by nuclear BRN3A staining Data represented as meanā±āSEM. *Pā<ā0.05, **Pā<ā0.01 by 1-way ANOVA with Tukeyās HSD post-test.